Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
Conditions
- Opiate Dependence
- Human Immunodeficiency Virus
Interventions
- DRUG: injectable naltrexone
- DRUG: placebo comparator
Sponsor
University of Pennsylvania
Collaborators